Taiwan Set To Approve Human Trials Of Locally Made Bird Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
Taiwanese health authorities expect the nation's emergency H5N1 vaccine to undergo its first human clinical trial by the end of this year. The vaccine was developed by the National Health Research Institute to use only in case of an emergency outbreak of the bird flu virus. The Department of Health is expected to authorize the trials by July 1. The restriction to emergencies only results from the institute's limited capacity to produce the vaccine, but DoH is seeking a partner in the private sector to enable greater production. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.